Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
Status:
Terminated
Trial end date:
2020-11-05
Target enrollment:
Participant gender:
Summary
This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and
stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before
nivolumab in patients with metastatic squamous or non-squamous non-small cell lung carcinoma
(NSCLC) and metastatic uveal melanoma. In situ gene therapy will consist of
adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus
Valacyclovir therapy.